In the last trading session, 1.0 million Syndax Pharmaceuticals Inc (NASDAQ:SNDX) shares changed hands as the company’s beta touched 1.26. With the company’s per share price at $12.61 changed hands at -$0.43 or -3.30% during last session, the market valuation stood at $1.08B. SNDX’s last price was a discount, traded about -98.81% off its 52-week high of $25.07. The share price had its 52-week low at $12.06, which suggests the last value was 4.36% up since then. When we look at Syndax Pharmaceuticals Inc’s average trading volume, we note the 10-day average is 1.74 million shares, with the 3-month average coming to 2.45 million.
Analysts gave the Syndax Pharmaceuticals Inc (SNDX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.20. If we narrow down to specifics, the data shows that 0 out of 4 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended SNDX as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight. Syndax Pharmaceuticals Inc’s EPS for the current quarter is expected to be -1.24.
Syndax Pharmaceuticals Inc (NASDAQ:SNDX) trade information
Instantly SNDX was in red as seen at the end of in last trading. With action -3.00%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -4.61%, with the 5-day performance at -3.00% in the red. However, in the 30-day time frame, Syndax Pharmaceuticals Inc (NASDAQ:SNDX) is -15.48% down. Looking at the short shares, we see there were 19.2 million shares sold at short interest cover period of 7.85 days.
The consensus price target for the stock as assigned by Wall Street analysts is 27.5, meaning bulls need an upside of 54.15% from its current market value. According to analyst projections, SNDX’s forecast low is 18 with 37 as the target high. To hit the forecast high, the stock’s price needs a -193.42% plunge from its current level, while the stock would need to soar -42.74% for it to hit the projected low.
Syndax Pharmaceuticals Inc (SNDX) estimates and forecasts
Year-over-year growth is forecast to reach 277.26% up from the last financial year.
Consensus estimates given by 13 financial analysts project the company’s revenue in the current quarter to hit an average of 15.43M. 12 analysts are of the opinion that Syndax Pharmaceuticals Inc’s revenue for the current quarter will be 18.68M. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 433.64%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -15.16%. The 2025 estimates are for Syndax Pharmaceuticals Inc earnings to decrease by -3.14%, but the outlook for the next 5-year period is at 27.23% per year.
SNDX Dividends
Syndax Pharmaceuticals Inc is expected to release its next quarterly earnings report on 2025-Mar-02.
Syndax Pharmaceuticals Inc (NASDAQ:SNDX)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 1.31% of Syndax Pharmaceuticals Inc shares while 116.29% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 117.83%. There are 116.29% institutions holding the Syndax Pharmaceuticals Inc stock share, with BLACKROCK INC. the top institutional holder. As of 2024-06-30, the company held 9.2788% of the shares, roughly 7.91 million SNDX shares worth $162.33 million.
WELLINGTON MANAGEMENT GROUP LLP holds the second largest percentage of outstanding shares, with 8.6063% or 7.34 million shares worth $150.67 million as of 2024-06-30.
Among Mutual Funds, the top two as of Oct 31, 2024 were Vanguard Specialized-Health Care Fund and Vanguard Total Stock Market Index Fund . With 2.99 shares estimated at $37.67 million under it, the former controlled 3.47% of total outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held about 2.97% of the shares, roughly 2.55 shares worth around $32.19 million.
